The market expects Thermo Fisher Scientific (TMO) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known ...

Now some of this was due to tougher comparisons as Thermo Fisher did great business in 2020 and 2021 as drug companies spent fortunes trying to figure out how to fight Covid. Afterwards ...

--(BUSINESS WIRE)--Lyndra Therapeutics, a clinical-stage biopharmaceutical company pioneering long-acting oral therapies, today announced a strategic collaboration with Thermo Fisher Scientific ...

Morgan Stanley analyst Tejas Savant maintained a Buy rating on Thermo Fisher (TMO – Research Report) today and set a price target of $647.00.

In a report released today, Eve Burstein from Bernstein maintained a Buy rating on Thermo Fisher (TMO – Research Report), with a price target ...

Highlights from the first day included updates from several firms about their China businesses and M&A strategies.